

TRANSMITTAL  
FORM



Application Number: 09/998,009  
Filing Date: November 28, 2001  
First Named Inventor: Marina Konopleva  
Art Unit: 1635  
Examiner Name: R. Cook

Total Number of Pages in this Submission: 20

Attorney Docket Number: UTSC:652US

## ENCLOSURES (check all that apply)

- |   |   |  |
|---|---|--|
| <input type="checkbox"/> Fee Transmittal Form<br><input type="checkbox"/> Fee Attached<br><input type="checkbox"/> Amendment/Reply<br><input type="checkbox"/> After Final<br><input type="checkbox"/> Affidavits/declaration(s)<br><input type="checkbox"/> Extension of Time Request<br><input type="checkbox"/> Express Abandonment Request<br><input type="checkbox"/> Information Disclosure Statement<br><input type="checkbox"/> Form PTO-1449<br><input type="checkbox"/> References _____<br><input type="checkbox"/> Certified Copy of Priority Documents<br><input type="checkbox"/> Reply to Missing Parts/Incomplete Application<br><input type="checkbox"/> Reply to Missing Parts/Requirements<br><input type="checkbox"/> Declaration(s) _____<br><input type="checkbox"/> Copy of Notice of Missing Parts/Requirements | <input type="checkbox"/> Drawings(s) _____<br><input type="checkbox"/> Licensing-related Papers<br><input type="checkbox"/> Petition<br><input type="checkbox"/> Petition to Convert to a Provisional Application<br><input type="checkbox"/> Power of Attorney, Revocation, Change of Correspondence Address<br><input type="checkbox"/> Statement under 37 CFR §3.73(b)<br><input type="checkbox"/> Designation of Patent Practitioners<br><input type="checkbox"/> Terminal Disclaimer<br><input type="checkbox"/> Request for Refund<br><input type="checkbox"/> CD, Number CD(s) _____<br><input type="checkbox"/> Landscape Table on CD | <input type="checkbox"/> After Allowance Communication to TC<br><input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences<br><input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)<br><input type="checkbox"/> Proprietary Information<br><input type="checkbox"/> Status Letter<br><input checked="" type="checkbox"/> Other Enclosure(s) (please identify below)<br><input type="checkbox"/> Check in the amount of \$ _____<br><input checked="" type="checkbox"/> Authorized to be charged to deposit account if check insufficient or inadvertently omitted<br>Deposit account number: <u>50-1212/UTSC:652US</u><br><input type="checkbox"/> Sequence Statement<br><input type="checkbox"/> Paper Copy of Sequence Listing<br><input type="checkbox"/> Computer Readable Form (CRF)<br><input checked="" type="checkbox"/> Postcard<br><input checked="" type="checkbox"/> Declaration Under 37 C.F.R. §1.132<br><input type="checkbox"/> _____ |
|---|---|--|

Remarks:

## SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	Fulbright & Jaworski, L.L.P.	Customer Number	32425
Signature			
Printed Name	Steven L. Highlander	Reg. No.	37,642
Date	August 23, 2005		

## CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:


Signature			
Typed or Printed Name	Steven L. Highlander	Date	August 23, 2005



CERTIFICATE OF MAILING  
37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450, on the date below:

August 23, 2005  
Date

  
Steven L. Highlander

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

*In re* Application of:  
Marina Konopleva *et al.*

Serial No.: 09/998,009

Filed: November 28, 2001

For: CDDO-COMPOUNDS AND  
COMBINATION THERAPIES THEREOF

Group Art Unit: 1635

Examiner: R. Cook

Atty. Dkt. No.: UTSC:652US/SLH

**DECLARATION UNDER 37 C.F.R. §1.132**

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

We, the undersigned, do declare that:

1. We are the named inventors of the above-captioned application.
2. We are the authors of Konopleva *et al.*, *Blood* 96(11) Part 1, pp.121a, 2000. Also listed as authors on that abstract were Irina Stiouf, Zeev Estrov, Twee Tsao, David Harris, Mark Munsell, Clinton Leysath, Shourong Zhao, Ellen C. Jackson, and Shi-rong Chang.

3. The contributions for each of these individuals is set forth below:

**Irina Stiouf** was a post-doctoral fellow who developed several flow cytometry assays utilized in this study by the inventors.

**Zeev Estrov** was a co-director of the tissue culture core in the AML-PO1 grant who directed clonogenic assays upon request of the inventors.

**Twee Tsao** was a technical assistant (Senior Research Assistant in Dr. Andreeff's laboratory) who performed protein analysis as directed by the inventors.

**David Harris** was a technical assistant (Research Assistant in Dr. Estrov's laboratory) who performed clonogenic assays as directed by the inventors.

**Mark Munsell** provided statistical analysis for publication.

**Clinton Leysath** was a technical assistant (Research Assistant in Dr. Andreeff's laboratory) who conducted tissue culture and flow cytometry experiments under supervision of the inventors.


**Shourong Zhao** was an instructor who provided expertise in Western blot analysis and PCR.

**Ellen C. Jackson** was a Research Nurse who provided clinical information about AML samples were used.

**Shi-rong Chang** was a technical assistant (Research Assistant in Dr. Andreeff's laboratory) who validated conditions for Western blot analysis of several proteins utilized by the inventors in the current study.

4. Thus, these individuals did not contribute conceptually to the subject matter of the above-captioned application, and thus were properly not listed as inventors thereon.

- 8/10/2005  
Date


  
Marina Konopleva, MD, PhD

Date \_\_\_\_\_

---

Michael Sporn, MD

Date 8/14/05

  
Michael Andreeff, MD, PhD